Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

A five-year trial of the weight loss drug tirzepatide in Greater Manchester was announced last October ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment ...

India’s drug regulator has given the nod to Eli Lilly’s once-a- week Mounjaro (tirzepatide) injection in the KwikPen format, ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.